Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options.

He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients.

Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham.

His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematologic malignancies, lymphomas and stem cell transplantation.

Professor Martin Kaiser and Dr Matthew Jenner discuss the BSH Good Practice Paper for the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients, published in July 2024.

Professor Guy Pratt discusses the investigation, diagnosis and management of smouldering myeloma. This podcast is based on the British Society for Haematology’s 2024 Good Practice Paper, Diagnosis and management of smouldering myeloma.